Patents by Inventor Nikolia Khramtsov

Nikolia Khramtsov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
    Publication number: 20170218067
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: February 24, 2017
    Publication date: August 3, 2017
    Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
  • Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
    Patent number: 9580503
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: February 28, 2017
    Assignees: Celldex Therapeutics, Inc., Amgen Fremont Inc.
    Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
  • ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF
    Publication number: 20120251555
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: November 29, 2011
    Publication date: October 4, 2012
    Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
  • Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
    Patent number: 8067544
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: November 29, 2011
    Assignee: Curagen Corporation
    Inventors: Gregory M. Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Fai Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov
  • Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
    Publication number: 20050084449
    Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: March 19, 2004
    Publication date: April 21, 2005
    Inventors: Gregory Landes, Francine Chen, Binyam Bezabeh, Ian Foltz, Kam Tse, Michael Jeffers, Mehdi Mesri, Gary Starling, Peter Mezes, Nikolia Khramtsov